Healthcare - Medical - Healthcare Information Services - NASDAQ - US
$ 0.1633
-3.88 %
$ 1.66 M
Market Cap
-0.04
P/E
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.[ Read More ]
The intrinsic value of one ACON stock under the base case scenario is HIDDEN Compared to the current market price of 0.163 USD, Aclarion, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ACON
FINANCIALS
75.4 K
REVENUE
-4.88 M
OPERATING INCOME
-4.91 M
NET INCOME
-3.65 M
OPERATING CASH FLOW
-120 K
INVESTING CASH FLOW
3.31 M
FINANCING CASH FLOW
14.4 K
REVENUE
-1.3 M
OPERATING INCOME
-1.37 M
NET INCOME
-800 K
OPERATING CASH FLOW
-104 K
INVESTING CASH FLOW
1.04 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Aclarion, Inc.
| Current Assets | 1.29 M |
| Cash & Short-Term Investments | 1.02 M |
| Receivables | 13.4 K |
| Other Current Assets | 255 K |
| Non-Current Assets | 1.17 M |
| Long-Term Investments | 0 |
| PP&E | 1.78 K |
| Other Non-Current Assets | 1.17 M |
| Current Liabilities | 3.19 M |
| Accounts Payable | 761 K |
| Short-Term Debt | 1.13 M |
| Other Current Liabilities | 1.3 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Aclarion, Inc.
| Revenue | 75.4 K |
| Cost Of Revenue | 75.7 K |
| Gross Profit | -324 |
| Operating Expenses | 4.88 M |
| Operating Income | -4.88 M |
| Other Expenses | 35.4 K |
| Net Income | -4.91 M |
RATIOS
-0.43%
GROSS MARGIN
-6466.48%
OPERATING MARGIN
-6513.41%
NET MARGIN
674.64%
ROE
-199.67%
ROA
-1225.96%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aclarion, Inc.
| Net Income | -4.91 M |
| Depreciation & Amortization | 163 K |
| Capital Expenditures | -120 K |
| Stock-Based Compensation | 456 K |
| Change in Working Capital | 623 K |
| Others | 427 K |
| Free Cash Flow | -3.77 M |
Wall Street Analysts Price Targets
Aclarion, Inc.
ACON has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.70%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Aclarion, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
Feb 16, 2023
|
Bought 1 K USD
|
Thramann Jeffrey John
Executive Chairman |
+ 1
|
1000 USD |
|
1 year ago
Dec 29, 2022
|
Bought 4.47 K USD
|
Ness Brent
Chief Executive Officer |
+ 7711
|
0.58 USD |
|
1 year ago
Dec 29, 2022
|
Bought 4.34 K USD
|
Ness Brent
Chief Executive Officer |
+ 8500
|
0.51 USD |
|
1 year ago
Dec 28, 2022
|
Bought 961 USD
|
Ness Brent
Chief Executive Officer |
+ 2289
|
0.42 USD |
|
1 year ago
Dec 29, 2022
|
Bought 8.24 K USD
|
Lorbiecki John Paul
Chief Financial Officer |
+ 18304.441
|
0.45 USD |
|
1 year ago
Dec 29, 2022
|
Bought 1.76 K USD
|
Lorbiecki John Paul
Chief Financial Officer |
+ 4100
|
0.43 USD |
|
2 years ago
Apr 22, 2022
|
Bought 15.3 K USD
|
Bond Ryan
Chief Strategy Officer |
+ 21000
|
0.73 USD |
|
2 years ago
Apr 21, 2022
|
Bought 47.8 K USD
|
Wesemann William
director: |
+ 11000
|
4.35 USD |
|
2 years ago
Apr 21, 2022
|
Bought 47.8 K USD
|
Wesemann William
Director |
+ 11000
|
4.35 USD |
|
2 years ago
Apr 21, 2022
|
Bought 0 USD
|
Ness Brent
Chief Executive Officer |
+ 1000
|
0 USD |
|
2 years ago
Apr 21, 2022
|
Bought 0 USD
|
Neal David K
director: |
+ 34400
|
0 USD |
7. News
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
BROOMFIELD, CO / ACCESSWIRE / November 14, 2024 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq:ACON)(Nasdaq:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its participation at the upcoming Virtual Investor Summit Microcap Event on November 21st. The Company will be available for 1-on-1 meetings throughout the day in addition to its formal presentation.
accesswire.com
- 2 days ago
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion's CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15th, 2024, at 2:00 p.m.
globenewswire.com
- 1 month ago
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help Stratify MC Patients to Potentially Inform Better Treatment Decisions for cLBP Patients Results Presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024 BROOMFIELD, CO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that the Nociscan solution was utilized to better understand Modic changes (MC) in patients suffering from chronic low back pain (cLBP).
globenewswire.com
- 1 month ago
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON).
globenewswire.com
- 2 months ago
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions
globenewswire.com
- 2 months ago
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
Initial LIFEHAB Enrolled Patients Receive Nociscan Exams to Help Evaluate How Biomarkers in the Discs of the Lumbar Spine Correspond With Treatment Response
globenewswire.com
- 2 months ago
Aclarion Added to PRISM Emerging Medical Devices Index
NEW YORK, September 06, 2024 – PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index, which highlights companies at the forefront of innovation and market disruption in the medtech sector.
prismmediawire.com
- 2 months ago
Aclarion Added to PRISM Emerging Medical Devices Index
Company's industry-first technology addresses chronic low back pain Aclarion secured its first commercial agreement with Michigan's Sheridan Community Hospital PRISM Emerging Medical Devices Index features companies at forefront of innovation and market disruption in medtech NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index, which highlights companies at the forefront of innovation and market disruption in the medtech sector.
globenewswire.com
- 2 months ago
Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market
Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population
globenewswire.com
- 2 months ago
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey
CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain
globenewswire.com
- 2 months ago
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans
Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data
globenewswire.com
- 2 months ago
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the upcoming Virtual Investor Summit on August 20th, 2024. Investors may request a one-on-one meeting with management by registering here: https://investorsummitgroup.com .
globenewswire.com
- 3 months ago
8. Profile Summary
Aclarion, Inc. ACON
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 1.66 M
Dividend Yield
0.70%
Description
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Contact
951 Mariners Island Boulevard, San Mateo, CA, 94404
https://www.aclarion.com
IPO Date
April 22, 2022
Employees
4
Officers
Mr. Brent Ness
Chief Executive Officer, President & Director
Mr. John Lorbiecki
Chief Financial Officer
Dr. Jeffrey John Thramann M.D.
Executive Chairman
Mr. Ryan Bond
Chief Strategy Officer